Citations

Clear

313 citation(s) found for "Alvarez, P".

Clinical and Radiographic Features of Giant Cell Arteritis With Intracranial Involvement
Sánchez-Álvarez, Catalina , Hawkins, Alexander S., Koster, Matthew J. , Lehman, Vance T. , Crowson, Cynthia S. , Sanchez-Alvarez, Catalina , Koster, Matthew J , Warrington, Kenneth J.

Mayo Clinic

ACR Open Rheumatology | July 22, 2020 | Volume: 2 | Issue: 8 | Pages: 471-477

10.1002/acr2.11161 | PMID 32697426 Get It

ObjectiveGiant cell arteritis (GCA) is a large‐vessel vasculitis that primarily affects the aorta and its branches. Extracranial branches of the carotid artery are frequently affected; however, intracranial involvement in GCA is rare.MethodsA retrospective medical record review was performed to identify all patients with intracranial GCA (IC‐GCA) from January 1996 through May 2018.ResultsNine patients with IC‐GCA were included (78% male; mean age, 72.1 years [SD: 7.9]). All patients met ACR criteria for GCA. The median time from onset of GCA to intracranial involvement was 0.6 months (interquartile range: 0.1‐5.1). All patients had neurologic symptoms, 89% had an ischemic cerebrovascular event. Transient or permanent vision loss was frequent (56% of patients). IC‐GCA was diagnosed by cranial imaging in all nine patients. Intracranial vasculitis most commonly affected the internal carotid artery (100%), followed by the vertebral artery (67%), posterior cerebral artery (67%), middle cerebral artery (44%), anterior cerebral artery (33%), and posterior inferior cerebral artery (11%). Intracranial vessel stenosis was present in 89%, occlusion in 33%, wall thickening in 33%, and dilation in 11%.All patients received glucocorticoids. Additional therapeutic agents included cyclophosphamide (67%) and tocilizumab (22%). Despite treatment, five patients had rapid deterioration and mortality. Comparing IC‐GCA patient survival to the expected rates from the US population, the standardized mortality ratio (95% CI) for IC‐GCA was 58.1 (18.9‐135.6).ConclusionAlthough rare, IC‐GCA is associated with significant morbidity and mortality. It occurs predominantly in men and presents with ischemic cerebrovascular events. Current treatment strategies appear to be of limited efficacy for IC‐GCA.
Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients
Barrera, Francisco J. , Shekhar, Skand , Wurth, Rachel , Moreno‐Peña, Pablo J. , Ponce, Oscar J. , Hajdenberg, Michelle , Álvarez‐Villalobos, Neri Alejandro , Schiffrin, Ernesto L. , Eisenhofer, Graeme , Porter, Forbes D. , Brito, Juan P. , Bornstein, Stefan R. , González‐González, José Gerardo , Rodríguez‐Gutiérrez, René , Hannah‐Shmouni, Fady , Alvarez-Villalobos, Neri A, Schiffrin, Ernesto L , Eisenhofer, Graeme , Bornstein, Stefan R , Stratakis, Constantine A , González-González, José Gerardo , Rodíguez-Gutiérrez, René, Hannah-Shmouni, Fady , Álvarez-Villalobos, Neri A , Brito, Juan P , Ponce, Oscar Josue , Hall, Janet Elizabeth , Stratakis, Constantine A.

Mayo Clinic

Journal of the Endocrine Society | July 21, 2020 | Volume: 4 | Issue: 9 | Pages: No page available

10.1210/jendso/bvaa102 | PMID 32885126 Get It

Abstract Coronavirus disease 2019 (Covid-19) has affected millions of people and may disproportionately affect those with hypertension and diabetes. Because of inadequate methods in published systematic reviews, the prevalence of diabetes and hypertension and associated risks of poor outcomes in Covid-19 patients are unknown. We searched databases from December 1, 2019, to April 6, 2020, and selected observational peer-reviewed studies in English of patients with Covid-19. Independent reviewers extracted data on study participants, interventions, and outcomes and assessed risk of bias, and the certainty of evidence. We included 65 (15 794 participants) observational studies at moderate to high risk of bias. Overall prevalence of diabetes and hypertension was 12% (95% confidence interval [CI], 10-15; n = 12 870; I2: 89%), and 17% (95% CI, 13-22; n = 12 709; I2: 95%), respectively. In severe Covid-19, the prevalence of diabetes and hypertension were 18% (95% CI, 16-20; n = 1099; I2: 0%) and 32% (95% CI, 16-54; n = 1078; I2: 63%), respectively. Unadjusted relative risk for intensive care unit admission and mortality were 1.96 (95% CI, 1.19-3.22; n = 8890; I2: 80%; P = .008) and 2.78 (95% CI, 1.39-5.58; n = 2058; I2: 75%; P = .0004) for diabetics; and 2.95 (95% CI, 2.18-3.99; n = 1737; I2: 0%; P < .001) and 2.39 (95% CI, 1.54-3.73; n = 3107; I2: 66%; P < .001) for hypertensives. Neither diabetes (1.50; 95% CI, 0.90-2.50; n = 1991; I2: 74%; P = .119) nor hypertension (1.48; 95% CI, 0.99-2.23; n = 2023; I2: 69%; P = .058) was associated with severe Covid-19. In conclusion, the risk of intensive care unit admission and mortality for patients with diabetes or hypertension who developed Covid-19 is increased compared with those without these comorbidities. PROSPERO registration number CRD42020176582.
Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries
Cardona, Andrés F. , Ruíz-Patiño, Alejandro , Sotelo, Carolina , Zamudio-Molano, Nataly, Zatarain-Barrón, Zyanya Lucía , Ricaurte, Luisa , Álvarez, Marco Polo Peralta , Barrón, Feliciano , Rojas, Leonardo , Rolfo, Christian , Karachaliou, Niki , Molina‐Vila, Miguel Ángel , Cardona, Andrés F , Sotelo-Rodríguez, Carolina , Rojas, Leonardo , Arrieta, Óscar , Raez, Luis , Rosell, Rafael

Mayo Clinic

Therapeutic Advances in Respiratory Disease | July 9, 2020 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/1753466620938553 | PMID 32643553 Get It

Precision oncology is the field that places emphasis on the diagnosis and treatment of tumors that harbor specific genomic alterations susceptible to inhibition or modulation. Although most alterations are only present in a minority of patients, a substantial effect on survival can be observed in this subgroup. Mass genome sequencing has led to the identification of a specific driver in the translocations of the tropomyosin receptor kinase family (NTRK) in a subset of rare tumors both in children and in adults, and to the development and investigation of Larotrectinib. This medication was granted approval by the US Food and Drug Administration for NTRK-positive tumors, regardless of histology or age group, as such, larotrectinib was the first in its kind to be approved under the premise that molecular pattern is more important than histology in terms of therapeutic approach. It yielded significant results in disease control with good tolerability across a wide range of diseases including rare pediatric tumors, salivary gland tumors, gliomas, soft-tissue sarcomas, and thyroid carcinomas. In addition, and by taking different approaches in clinical trial design and conducting allocation based on biomarkers, the effects of target therapies can be isolated and quantified. Moreover, and considering developing nations and resource-limited settings, precision oncology could offer a tool to reduce cancer-related disability and hospital costs. In addition, developing nations also present patients with rare tumors that lack a chance of treatment, outside of clinical trials. This, in turn, offers the possibility for international collaboration, and contributes to employment, education, and health service provisions. The reviews of this paper are available via the supplemental material section.
Tuberculous peritonitis masquerading as carcinomatosis
Motoa, Gabriel , Álvarez, Salvador

Mayo Clinic

Clinical Case Reports | June 23, 2020 | Volume: 8 | Issue: 10 | Pages: 2078-2079

10.1002/ccr3.3040 | PMID 33088559 Get It

AbstractTuberculous peritonitis may debut with unspecific symptoms that can pose a diagnostic challenge for clinicians. We present a patient with tuberculous peritonitis masquerading as carcinomatosis. High clinical suspicion, appropriate identification of bacterial isolates of the Mycobacterium tuberculosis complex, and susceptibility testing are crucial to select target therapy.
Coccidioides in lung transplant: case report
Diaz, Mark Anthony , Bayo, Maria Luisa, Alvarez, Francisco , Álvarez, Salvador

Mayo Clinic

BMJ Case Reports | April 17, 2020 | Volume: 13 | Issue: 4 | Pages: e230888

10.1136/bcr-2019-230888 | PMID 32303525 Get It

A middle-aged woman was hospitalised for generalised, painful skin lesions 6 weeks after a successful double-lung transplant. She had end-stage lung disease associated with chronic obstructive pulmonary disease due to alpha-1 antitrypsin deficiency, and she had been treated with itraconazole for 16 months because of lung infection associated with Malbranchea spp. Results of a skin biopsy of the initial lesion on her arm showed non-specific dermal inflammation, presumably due to reactivation of the Malbranchea spp infection. Follow-up cervical lymph node biopsy and culture showed Coccidioides posadasii/C. immitis. A detailed review of her travel history showed a 4-month stay in Arizona as a teenager that she barely remembered. Coccidioides spp were likely misidentified as Malbranchea spp owing to similar morphological characteristics. Dosages of immunosuppressive medications were reduced, and antifungal therapy was changed to posaconazole. Her skin lesions resolved.
Diagnostic Accuracy of the Triglyceride and Glucose Index for Insulin Resistance: A Systematic Review
Sánchez‐García, Adriana , Rodríguez‐Gutiérrez, René , Mancillas‐Adame, Leonardo , González‐Nava, Victoria , González-Colmenero, Alejandro Díaz , Solís, Ricardo César , Álvarez‐Villalobos, Neri Alejandro , González‐González, José Gerardo , Diaz Gonzalez-Colmenero, Alejandro , González-González, José Gerardo , Solis-Pacheco, Ricardo Cesar , Álvarez-Villalobos, Neri A , Sánchez-García, Adriana

Mayo Clinic

International Journal of Endocrinology | March 10, 2020 | Volume: 2020 | Issue: No issue available | Pages: 1-7

10.1155/2020/4678526 | PMID 32256572 Get It

Introduction . The triglyceride and glucose (TyG) index has been described as a biochemical marker of insulin resistance (IR); however, its diagnostic accuracy remains uncertain. Objective . To summarize the evidence assessing the diagnostic accuracy of the TyG index regarding IR. Methods . A comprehensive search in MEDLINE, EMBASE, Web of Science, and Scopus was performed without any language restriction. Studies assessing the diagnostic accuracy of the TyG index against the hyperinsulinemic-euglycemic clamp (HIEC) or any other IR biochemical were assessed independently and in duplicate. Diagnostic accuracy measures (sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratios) were extracted independently and in duplicate. The QUADAS-2 tool was used to assess the risk of bias of independent studies. Results . We identified 15 eligible studies with 69,922 participants and an overall quality of low to moderate. The TyG index was evaluated by HIEC and HOMA as reference tests. The highest achieved sensitivity was 96% using HIEC, and the highest specificity was of 99% using HOMA-IR, with a cutoff value of 4.68. AUC values varied from 0.59 to 0.88. Cutoff values for IR were variable between studies, limiting its comparability. Conclusion . In this systematic review, we found moderate-to-low quality evidence about the usefulness of the TyG index as a surrogate biochemical marker of IR. Due to the lack of a standardized IR definition and heterogeneity between studies, further validation and standardized cutoff values are needed to be used in clinical practice.
Doctor YouTube’s opinion on seasonal influenza: A critical appraisal of the information available to patients
Kallur, Akhil , Albalbissi, Ahmad, Carillo-Martin, Ismael, Kallur, Lakshmi, Kherallah, Yaman, Mahajan, Akhilesh, Mahapatra, Shayan , Mohan, Kaushik, Mohan, Priyasree, Reddy, Keerti, Sankhyan, Pratyaksha, López-Álvarez, Sonia , Youssef, Dima, Abbassi, Adel M El, Gonzalez-Estrada, Alexei , Boonpheng, Boonphiphop , ABBASSI, ADEL M EL, Gonzalez‐Estrada, Alexei

Mayo Clinic

DIGITAL HEALTH | February 17, 2020 | Volume: 6 | Issue: No issue available | Pages: No page available

10.1177/2055207620906968 | PMID 32110430 Get It

Background Seasonal influenza is a respiratory illness caused by the influenza virus. During the 2017–2018 flu season, the Centers for Disease Control and Prevention noted approximately 959,000 hospitalizations and 79,400 deaths from influenza. We sought to evaluate the educational quality of informational videos pertaining to seasonal influenza on the popular social media forum, YouTube. Methods Using the keywords “seasonal influenza,” all videos from 28 January to 5 February 2017 were included and analyzed for characteristics, source, and content. The source was further classified as healthcare provider, alternative-medicine provider, the patient and/or their parents, company, media, or professional society. Videos about other categories of influenza (e.g. swine or Spanish) or in foreign languages were excluded. A total of 10 blinded reviewers scored each video independently. Results Overall, 300 videos were analyzed, with a median of 341.50 views, 1.00 likes, 0 dislikes, and 0 comments. Based on the average scores of videos by source, there was statistically significant difference in the average score among videos by video source ( p < 0.01). Healthcare provider videos had the highest mean scores whereas alternative medicine provider videos had the lowest. Conclusions Although the aforementioned video sources scored higher than others, these videos did not fulfill our criteria as far as educating patients thoroughly. Our data also suggest alternative medicine and patient source videos were misleading for patients. Clinical implications: Although videos by healthcare providers were a better source of information, videos on seasonal influenza were shown to be poor sources of valid healthcare information. This study reiterates the need for higher-quality educational videos on seasonal influenza by the medical community.
Effect of Normal Saline Injections on Lateral Epicondylitis Symptoms: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Acosta‐Olivo, Carlos , Millán-Alanís, Juan Manuel , Álvarez‐Villalobos, Neri Alejandro , Vílchez‐Cavazos, Félix , Peña‐Martínez, Víctor M. , Simental‐Mendía, Mario , Alvarez-Villalobos, Neri, Álvarez-Villalobos, Neri A , Simental‐Mendía, Luis E.

Mayo Clinic

The American Journal of Sports Medicine | February 11, 2020 | Volume: 48 | Issue: 12 | Pages: 3094-3102

10.1177/0363546519899644 | PMID 32045280 Get It

Background: Lateral epicondylitis, or tennis elbow, is a painful degenerative disorder that commonly occurs in adults between 40 and 60 years of age. Normal saline (NS) injections have been used as placebo through a large number of randomized controlled trials (RCTs) focused on the treatment of lateral epicondylitis. Purpose: This meta-analysis of RCTs aimed to assess the therapeutic effect of NS injections on lateral epicondylitis symptoms and compare results with established minimal clinically important difference criteria. Study Design: Systematic review and meta-analysis. Methods: MEDLINE, Embase, Web of Science, and Scopus databases were searched for clinical trials reporting pain and joint function with the visual analog scale, Patient-Rated Tennis Elbow Evaluation, and Disabilities of the Arm, Shoulder and Hand in patients with lateral epicondylitis. The meta-analysis was conducted with a random effects model and generic inverse variance method. Heterogeneity was tested with the I 2 statistic index. Results: A total of 15 RCTs included in this meta-analysis revealed a significant improvement in pain (mean difference, 3.61 cm [95% CI, 2.29-4.92 cm]; P < .00001; I 2 = 88%; visual analog scale) and function (mean difference, 25.65 [95% CI, 13.30-37.99]; P < .0001; I 2 = 82%; Patient-Rated Tennis Elbow Evaluation / Disabilities of the Arm, Shoulder and Hand) after NS injection (≥6 months). Conclusion: NS injections yielded a statistically significant and clinically meaningful improvement in pain and functional outcomes in patients with lateral epicondylitis. New research should focus on better methods to diminish the potential confounders that could lead to this effect because NS injections could mask the real effect of an active therapeutic intervention in RCT. Registration: CRD42019127547 (PROSPERO).
A systematic review of pharmacological therapies and their effectiveness on health-related quality of life outcomes in patients with juvenile-onset systemic lupus erythematosus
Cintrón, Dahima , Millán-Alanís, Juan Manuel , Álvarez-Villalobos, N, Rodríguez‐Gutiérrez, René , Álvarez‐Villalobos, Neri Alejandro , Cintrón, D , Álvarez-Villalobos, Neri A , Vilá, Luis M.

Mayo Clinic

Lupus | February 7, 2020 | Volume: 29 | Issue: 3 | Pages: 303-310

10.1177/0961203320904145 | PMID 32031032 Get It

Juvenile-onset systemic lupus erythematosus (JSLE) presents with an aggressive course and high morbidity associated with disease and treatment. JSLE patients have a poorer health-related quality of life (HRQoL) when compared with age-matched patients with other rheumatologic disorders. We aim to summarize the impact of current pharmacological therapies on the HRQoL of JSLE patients. Search strategies were developed across seven databases. Randomized clinical trials (RCTs) and cohort studies comparing interventions to standard therapy, placebo or pre-post cohort comparisons for more than 4 weeks were included. The outcome included self-reported scales compared at baseline and a therapeutic time point. Risk of bias was evaluated by using the Cochrane risk of bias tool and the Newcastle–Ottawa quality assessment scale. A total of 2812 articles were narrowed down to 309 for full-text screening. Four RCTs and one prospective cohort study, with a total of 634 JSLE patients, met the inclusion criteria. Four of the studies had a controlled intervention plus standard therapy compared with standard therapy alone or placebo. Multiple indices were used to evaluate HRQoL. These included the Pediatric Quality of Life Inventory, Childhood Health Assessment Questionnaire, Simple Measure of Impact of Lupus Erythematosus in Youngsters tool, Kids Fatigue Severity Scale and Child Depression Inventory. A single study reported a significant improvement while remaining studies reported no difference or failed to report the statistical analysis. Although HRQoL is significantly impaired in JSLE, evidence regarding its improvement is limited due to the small number of eligible studies, heterogeneity in scales, and HRQoL domains. A universal HRQoL questionnaire for JSLE needs to be established and used in both the research and clinical setting. All studies should adhere to reporting guidelines.